Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov;35(11):2121-7.
doi: 10.2337/dc12-0116. Epub 2012 Jul 6.

Curcumin Extract for Prevention of Type 2 Diabetes

Free PMC article
Randomized Controlled Trial

Curcumin Extract for Prevention of Type 2 Diabetes

Somlak Chuengsamarn et al. Diabetes Care. .
Free PMC article


Objective: To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population.

Research design and methods: This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention.

Results: After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group.

Conclusions: A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial.

Trial registration: NCT01052025.


Figure 1
Figure 1
Mean of parameters with SEM at baseline, 3, 6, and 9 months were compared between placebo- and curcumin-treated group. A: FPG. *P < 0.01. B: OGTT at 2 h. *P < 0.01. C: HbA1c. *P < 0.01. D: HOMA-β. *P < 0.01. E: C-peptide. *P < 0.05. F: HOMA-IR. *P < 0.001, #P < 0.05.

Comment in

Similar articles

See all similar articles

Cited by 93 articles

See all "Cited by" articles


    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053 - PubMed
    1. Hogan P, Dall T, Nikolov P, American Diabetes Association Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932 - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403 - PMC - PubMed
    1. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88–136 - PubMed
    1. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC, Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators Effect of Rosiglitazone and Ramipril on beta-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010;33:608–613 - PMC - PubMed

Publication types

Associated data